Immune booster shows promise against head and neck cancer
NCT ID NCT02641093
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study tests whether adding pembrolizumab, a drug that helps the immune system fight cancer, to standard treatment (surgery, radiation, and sometimes chemotherapy) can improve outcomes for people with head and neck cancer. About 96 participants who had surgery to remove their cancer will receive pembrolizumab along with radiation or chemoradiation. The goal is to see if this combination is safe and helps keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Louisville - James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.